Core Viewpoint - The company plans to issue 69.256 million shares, representing approximately 6.98% of its total issued shares, to raise funds for clinical trials and operational needs [1] Fundraising Details - The placement price is set at HKD 12.18 per share, which is about 4.0% lower than the closing price of HKD 12.69 on February 2 [1] - The total expected proceeds from the placement are approximately HKD 843.5 million, with a net amount of about HKD 835.3 million after expenses [1] Allocation of Proceeds - Approximately 90% of the net proceeds is intended for the preparation, groundwork, and initiation of global Phase III clinical trials for the obesity treatment small molecule oral GLP-1 receptor agonist ASC30 [1] - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [1]
歌礼制药-B拟折让约4%配售6925.6万股 净筹约8.353亿港元